Cohance Lifesciences Limited vs Fortis Healthcare Limited
Last updated: 5 November 2026
Cohance Lifesciences vs. Fortis Healthcare: A MoneyDock Comparison
MoneyDock analysts pit two prominent names in the Indian healthcare and life sciences sector against each other: Cohance Lifesciences Limited and Fortis Healthcare Limited. While both operate within the broader health domain, Cohance Lifesciences is engaged in pharmaceuticals and life sciences, focusing on areas like active pharmaceutical ingredients (APIs), specialty chemicals, and contract research and manufacturing services (CRAMS). Fortis Healthcare, on the other hand, is a leading integrated healthcare delivery service provider in India, primarily operating hospitals, diagnostics, and day care specialty facilities. This comparison aims to provide potential investors with a clear, data-driven perspective on these two companies, examining their current market standing and performance metrics.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences (COHANCE.NS) | Fortis Healthcare (FORTIS.NS) |
|---|---|---|
| Current Price | ₹449.00 | ₹819.80 |
| 52W High | ₹537.35 | ₹990.35 |
| 52W Low | ₹279.90 | ₹712.90 |
| 1-Year Return | -16.44% | -9.15% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating Cohance Lifesciences and Fortis Healthcare, several key aspects stand out from the provided data. Both companies currently show 'N/A' for Trailing P/E and Market Cap, which limits a direct valuation comparison based on these common metrics. However, we can still glean insights from their price movements and returns.
Valuation: Without Trailing P/E and Market Cap, a definitive statement on which stock is 'cheaper' or 'more expensive' in terms of valuation is difficult. However, Cohance's current price of ₹449.00 is further from its 52-week high of ₹537.35 compared to Fortis Healthcare, which trades at ₹819.80 against a 52-week high of ₹990.35. Cohance is also significantly above its 52-week low of ₹279.90, showing a substantial recovery or sustained interest from that point. Fortis, at ₹819.80, is also well above its 52-week low of ₹712.90, indicating relatively stronger price support at lower levels.
Returns: On the one-year return front, both companies have delivered negative returns, indicating a challenging period for both stocks. However, Fortis Healthcare (-9.15%) has outperformed Cohance Lifesciences (-16.44%) over the past year. This suggests that Fortis has experienced less severe price depreciation than Cohance, making it a 'winner' in terms of relative performance during this period.
Stability: The 52-week range can offer clues about price stability. Cohance Lifesciences has a wider 52-week range (₹279.90 to ₹537.35), representing a larger percentage swing from low to high relative to its current price. Fortis Healthcare has a narrower 52-week range (₹712.90 to ₹990.35), suggesting potentially less volatility in its price movements over the last year compared to Cohance. This could imply Fortis offers more relative stability, although both have seen significant dips from their highs. Fortis’s higher current price and a more contained 52-week range might appeal to investors looking for relatively less volatile assets within the sector.
MoneyDock Verdict
Given the available data, here's MoneyDock's take:
For Aggressive Investors: Cohance Lifesciences, trading further below its 52-week high and with a higher potential for volatility (indicated by its wider 52-week range relative to price), might offer a higher risk-reward proposition if a turnaround in the pharmaceutical and life sciences segment is anticipated. The larger dip in 1-year returns could also suggest a potentially greater rebound opportunity.
For Conservative Investors: Fortis Healthcare appears to be the more suitable choice. Its relatively narrower 52-week range and less severe 1-year negative return suggest greater price stability compared to Cohance. As a healthcare delivery provider, it might also be perceived as having more stable, albeit slower, growth prospects tied to population health needs.
For Long-term SIP Investors: Both companies are in important sectors, but with 'N/A' for P/E and Market Cap, a fundamental assessment is incomplete. However, for a long-term SIP, Fortis Healthcare's demonstrated resilience with a better 1-year return and potentially lower volatility might make it a more consistent option for compounding over time. Cohance could be considered for a long-term SIP if an investor has strong conviction in the growth of its specific life sciences sub-segments and is comfortable with higher short-term fluctuations.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.